Cancer
European approval for Roche’s Zelboraf
February 20, 2012Sales and Marketing Cancer, Roche, Yervoy, Zelboraf, melanoma
Roche’s skin cancer pill Zelboraf has been given European approval to treat advanced melanoma. Zelboraf (vemurafenib) is now available in …
NICE no for first line Tarceva
February 17, 2012Sales and Marketing CDF, Cancer, NICE, Roche, Tarceva
NICE no for first line Tarceva Watchdog wants more information on Roche’s drug NICE is not recommending Roche’s lung cancer …
Boehringer broadens afatinib studies
January 27, 2012Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, afatinib
Boehringer Ingelheim is expanding the scope of its studies into afatinib to test its use against head and neck cancers. …
Avastin now available in UK for ovarian cancer
January 17, 2012Sales and Marketing Cancer, Cancer Drugs Fund, NICE, Roche, avastin
Roche’s Avastin is now available as a treatment for women with ovarian cancer in the UK. Avastin (bevacizumab) can now …
New cancer drug costs escalating for NHS
December 13, 2011Cancer, NHS, oncology
New oncology drugs are pushing up the overall costs of treating cancer, according to a new report. The ‘Cancer Diagnosis …
No cancer link with Lantus, says Sanofi
December 7, 2011Sales and Marketing Cancer, Lantus, Sanofi, diabetes, insulin, safety
Sanofi has presented a new meta-analysis which suggests its insulin blockbuster Lantus does not raise the risk of cancer. A …
Abbott expands diagnostic pact with GlaxoSmithKline
November 29, 2011Research and Development, Sales and Marketing Abbott, Cancer, GSK, non-small cell lung cancer
Abbott will develop a diagnostic kit for GlaxoSmithKline’s new lung cancer drug candidate. This is an expansion of a …
Pancreatic cancer sees lowest improvement in cancer survival
November 23, 2011Medical Communications, Research and Development Cancer, Macmillan, pancreatic
A new cancer survival study shows that pancreatic cancer continues to have one of the worst mortality rates. The study …
Aslan licences promising cancer drug from Bristol-Myers Squibb
November 7, 2011Research and Development, Sales and Marketing Aslan, BMS, Cancer
Bristol-Myers Squibb has licensed one of its investigational oncology compounds, for the treatment of multiple solid tumours, to Singapore-based Aslan …
NICE blames pharma R&D model for spiralling cancer drug costs
September 29, 2011Research and Development, Sales and Marketing Cancer, NICE, clincial trials
NICE has blamed the pharma industry’s ‘inefficient’ and increasingly costly R&D model for the rising price of cancer drugs. NICE …
Cancer costs on an ‘unaffordable trajectory’
September 28, 2011Sales and Marketing Cancer, healthcare costs
The cost of cancer is rising too fast with new treatments giving uncertain benefits, according to a new study. A …
Roche to show new cancer data at European congress
September 20, 2011Research and Development Cancer, Roche, T-DM1, Zelboraf, avastin
Roche will highlight a range of new approaches in targeting cancer at the upcoming European cancer conference. In a series …
GSK-Merck back new developing world cancer charity
September 14, 2011Medical Communications Cancer, GSK, Merck & Co, Pink Ribbon-Red Ribbon, breast cancer, cervical cancer
GlaxoSmithKline and Merck are among the backers of a new charity that focuses on preventing female cancers in developing countries. …
FDA unveils changes to cancer drug review
September 14, 2011Research and Development, Sales and Marketing Cancer, FDA, regulatory affairs
The FDA has unveiled a reorganisation of how it reviews new cancer drugs, and says the new approach should help …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
